Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Can’t get you out of my spread
Investment Grade (IG) Credit is a major asset, for UK Defined Benefit (DB) schemes in particular, and it’s easy to see why. It’s simple, mean-revert
Motor Insurance Market Shift in H1 2025
After a year of record shopping and switching activity in 2024[i], the number of U.K. consumers searching for a better deal or switching motor insuran
Risk managers role in insuring physical climate risk
As nat cat protection gaps widen and climate events increase, you’ll need to grow your risk management toolkit and collaborate. How can you shape both

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.